Trial reportWorld journal of pediatrics : WJP2025
End-tidal CO corrected for ambient CO risk adjusted phototherapy threshold for the management of neonatal hyperbilirubinemia: a randomized clinical trial.
Trial report in World journal of pediatrics : WJP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The prediction of phototherapy by early postnatal ETCOc in Chinese newborns.BMC pediatrics · 2025Trial
- Can age-specific ETCOc determination predict the need for neonatal phototherapy?Pediatric research · 2026Article
- TabPFN-based explainable machine learning for predicting neonatal hyperbilirubinemia: A decade-long retrospective cohort study.Medicine · 2026Article
- Age-specific ETCOc measured by non-dispersive infrared spectroscopy predicts neonatal phototherapy.Pediatric research · 2026Article
- A LASSO-based nomogram for predicting acute bilirubin encephalopathy in newborns with severe hyperbilirubinemia.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundNeonatal hyperbilirubinemia risk factors determination is challenging due to the lack of quantifiable indicators for bilirubin production, resulting in phototherapy decisions made without real-time information. End-tidal carbon monoxide (CO) corrected for ambient CO (ETCOc) may be helpful for identifying hemolysis, but evidence on the application of ETCOc as a risk factor for the development of neonatal hyperbilirubinemia is scarce. This study aimed to evaluate whether the use of ETCOc to adjust neonatal hyperbilirubinemia risk categories and thus phototherapy thresholds can reduce the rate of phototherapy within the first seven days of life.
methodsThis is a randomized clinical trial including near-term and term infants with a transcutaneous bilirubin
resultsA total of 2500 infants were enrolled and randomized. Phototherapy within seven days of life occurred in 237 infants (18.9%) in the intervention group and 281 infants (22.5%) in the control group [adjusted relative risk: 0.85; 95% confidence interval (CI): 0.73, 0.98]. The ETCOc before phototherapy was 0.28 parts per million higher (95% CI: 0.10, 0.46) in the intervention group. The rate of subsequent severe hyperbilirubinemia was not significantly different, and other secondary outcomes were comparable between the two groups.
conclusionsFor near-term and term infants at risk of neonatal hyperbilirubinemia, the use of ETCOc to adjust neonatal hyperbilirubinemia risk categories can decrease the rate of phototherapy at seven days of life. Integrating the ETCOc to adjust the phototherapy threshold is helpful in the management of severe hyperbilirubinemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.